Rubius Therapeutics Inc.’s filing revealed that its CEO and President Appelhans Dannielle unloaded Company’s shares for reported $1323.0 on Feb 24. In the deal valued at $0.13 per share,10,385 shares were sold. As a result of this transaction, Appelhans Dannielle now holds 0 shares worth roughly $ 0.0.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Then, CAGNONI PABLO J sold 8,448 shares, generating $2,112 in total proceeds. Upon selling the shares at $0.25, the Director now owns 66,082 shares.
Before that, Appelhans Dannielle sold 3,878 shares. Rubius Therapeutics Inc. shares valued at $970 were divested by the CEO and President at a price of $0.25 per share. As a result of the transaction, Appelhans Dannielle now holds 10,385 shares, worth roughly $1557.75.
Guggenheim downgraded its Rubius Therapeutics Inc. [RUBY] rating to a Neutral from a a Buy in a research note published on Tuesday. SVB Leerink also remained covering RUBY and has decreased its forecast on March 13, 2020 with a “Mkt perform” recommendation from previously “an Outperform” rating. Morgan Stanley revised its rating on March 13, 2020. It rated RUBY as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of RUBY
On Tuesday, Rubius Therapeutics Inc. [NASDAQ:RUBY] saw its stock jump 11.20% to $0.15. On the same session, the stock had its day’s lowest price of $0.12, but rose to a high of $0.15. Over the last five days, the stock has lost -11.58%. Rubius Therapeutics Inc. shares have fallen nearly -16.63% since the year began. Nevertheless, the stocks have fallen -97.09% over the past one year. While a 52-week high of $6.18 was reached on 02/14/23, a 52-week low of $0.11 was recorded on 02/24/23. SMA at 50 days reached $0.2074, while 200 days put it at $0.5425. A total of 14.66 million shares were traded, compared to the trading of 5.49 million shares in the previous session.
Levels Of Support And Resistance For RUBY Stock
The 24-hour chart illustrates a support level at 0.1273, which if violated will result in even more drops to 0.1086. On the upside, there is a resistance level at 0.1573. A further resistance level may holdings at 0.1686. The Relative Strength Index (RSI) on the 14-day chart is 39.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0348, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.88%. Stochastics %K at 8.02% indicates the stock is a buying.
How much short interest is there in Rubius Therapeutics Inc.?
A steep rise in short interest was recorded in Rubius Therapeutics Inc. stocks on Jan 30, 2023, dropping by -0.17 million shares to a total of 1.87 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 2.04 million shares. There was a decline of -9.09%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 5.59% of the overall stock float, the days-to-cover ratio (short ratio) fell to 1.18.
Rubius Therapeutics Inc. [RUBY] – Who Are The Largest Shareholders?
In filings from Fidelity Management & Research Co, it is revealed that the company now owns 12,376,153 shares, or roughly 13.70% of the outstanding RUBY shares. In other words, the investor’s shares have fallen by -1,081,346 from its previous 13-F filing of 13457499.0. Additionally, Baillie Gifford & Co. increased 0.32% of its stake after which the total value it holdings stand at $1,270,842. Over the last quarter, The Vanguard Group, Inc. sold -28,619 shares of Rubius Therapeutics Inc., while Acadian Asset Management LLC sold 614,522 shares. At present, BlackRock Fund Advisors is holding 1,173,226 shares valued at $0.31 million. Michigan Department of Treasury owned 640,000 shares of the company at the time of its most recent 13F filing, worth $0.17 million.